We can observe that 61% of the preclinical studies included here focused their efforts on investigating the use of VNS for neuroprotection in stroke models, with specific outcomes in the activation of α7nAChR in five studies, in the different inflammatory mechanisms in seven studies, and in the volume of cerebral infarction in five studies and pro-angiogenic activity in four studies, placing neuroprotection as an important point of investigation before, during, or after an ischemic episode. Here, CHRNA7 is linked to stroke disorder.